Nature contains a wealth of microbial strains, genes, enzymes, metabolites, and other biomolecules, holding potential across diverse applications, including food processing, enzymatic modifications in detergents, pharmaceutical development, and biofuel production. Genomic analysis of varied microbial communities facilitates the study of these biomolecules.
BaseClear offers a strain discovery solution that enables the discovery and identification of novel microbial isolates. Our strain discovery platform allows high-throughput screening and analysis of microbial samples with the aim of discovering microbial strains with unique physiological and metabolic properties.
A customer was in demand of novel enzymes capable of degrading specified compounds under challenging acidophilic, thermophilic and alkalophilic conditions. Environmental samples and a wish list with high potential bacterial species were provided by the customer. The culturing approach included a heat shock, pre-culturing and parallel culturing conditions that were designed through customer consultations and literature search performed by a BaseClear expert, and optimized in pilot experiments. The obtained isolates were cultured to purity and their genome was sequenced to completeness and presented in the Genome Explorer for efficient data mining for novel enzymes.
This rigorous process led to the identification of twelve different species and thirty-two previously uncultured (novel) species, within the specified bacterial family. The customer received glycerol stocks of the pure cultures, fasta files of each sequenced isolate and a detailed expert report that included the experimental approach, result tables and relevant conclusions. The customer was granted complete intellectual property rights on the isolated strains, their genome sequences and present novel enzymes.
Traditional EFSA-compliant MIC testing can be costly for extensive strain evaluation. Our rapid antibiotic susceptibility screening assay enables larger-scale pre-screening for bacterial strains within the EFSA panel. This streamlines the selection of high-potential bacterial strains before proceeding to more focused EFSA-compliant microdilution testing, thereby optimizing research resources.
Our solution offers fast, high-throughput pre-screening for antibiotic susceptibility (non-EFSA compliant). Swift results with a minimal turnaround time of just 4 days* allow you to identify high-potential candidate strains before investing in EFSA-compliant MIC testing for a select few.
*Turnaround time may vary based on specific culture conditions, especially for species with slower growth rates.
Food and beverage industry: Novel microbial variants can lend desirable characteristics to food and beverage products, catering to changing consumer tastes and preferences, as well as enhancing the efficiency and quality of production processes.
Pharmaceutical companies: Identification of novel microbial strains with unique probiotic properties can be valuable for a healthy gut and health in general.
Agricultural sector: Novel microbial strains can promote to enhanced plant growth, improved nutrient uptake, or provide biocontrol against plant pathogens, contributing to sustainable agriculture practices.
Industrial biotechnology: Identification of strains with enzymes that can optimize various industrial processes, facilitate environmentally friendly bioremediation of pollutants, and enable the production of bio-based materials, offering sustainable alternatives to traditional materials.
Green industry: Novel strains can revolutionize green industries by wide array of applications such as biofuel production, carbon capture and utilization, water treatment, eco friendly solutions for specific chemical and textile production.